COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,388 Articles (22,816 medRxiv, 8,572 bioRxiv)

Most recent first Previous |  Page 822: Articles 8211-8220  | Next

Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022
Branda, F.
10.1101/2022.04.21.22273567 — Posted: 2022-04-27
Targeted genomic sequencing with probe capture for discovery and surveillance of coronaviruses in bats
Kuchinski, K. S., Loos, K. D., Suchan, D. M., Russell, J. N., Sies, A. N., Kumakamba, C., Muyembe, F., Mbala Kingebeni, P., Ngay Lukusa, I., NKawa, F., Atibu Losoma, J., Makuwa, M., Gillis, A., LeBreton, M., Ayukekbong, J. A., Monagin, C., Joly, D. O., Saylors, K., Wolfe, N. D., Rubin, E. M., Muyembe Tamfum, J. J., Prystajecky, N. A., McIver, D. J., Lange, C. E., Cameron, A. D. S.
10.1101/2022.04.25.489472 — Posted: 2022-04-26
Anti-SARS-Cov-2 S-RBD IgG formed after BNT162b2 vaccination can bind C1q and activate complement
Abu-Humaidan, A. H. A., Ahmad, F. M., Awajan, D., Jarrar, R., Alaridah, N.
10.1101/2022.04.24.489298 — Posted: 2022-04-26
A cocktail containing two synergetic antibodies broadly neutralizes SARS-CoV-2 and its variants including Omicron BA.1 and BA.2
Zhang, X., Luo, F., Zhang, H., Guo, H., Zhou, J., Li, T., Chen, S., Song, S., Shen, M., Wu, Y., Gao, Y., Han, X., Wang, Y., Hu, C., Lu, Y., Wang, W., Wang, K., Tang, N., Jin, T., Yang, C., Cheng, G., Yang, H., Jin, A., Ji, X., Gong, R., Chiu, S., Huang, A.
10.1101/2022.04.26.489529 — Posted: 2022-04-26
Global burden of mental health problems among children and adolescents during COVID-19 pandemic: A systematic umbrella review
Hossain, M. M., Nesa, F., Das, J., Aggad, R., Tasnim, S., Bairwa, M., Ma, P., Ramirez, G.
10.1101/2022.04.22.22274169 — Posted: 2022-04-26
Coronavirus and incomes: the COVID-19 pandemic dynamics in Africa in February 2022
Nesteruk, I., Rodionov, O.
10.1101/2022.04.22.22274058 — Posted: 2022-04-26
Excess all-cause mortality across counties in the United States, March 2020 to December 2021
Paglino, E., Lundberg, D. J., Cho, A., Wasserman, J. A., Raquib, R., Elo, I. T., Hempstead, K., Preston, S. H., Stokes, A. C.
10.1101/2022.04.23.22274192 — Posted: 2022-04-26
Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study.
Thuluva, S., Paradkar, V., Gunneri, S., Yerroju, V., Mogulla, R., Pothakamuri, S. V., Turaga, K., Kyasani, M., Manoharan, S., Adabala, S., Javvadi, A. S., Medigeshi, G. R., Singh, J., Shaman, H., Binayke, A., Aymaan, Z., Awasthi, A., Narang, M., N, P., Mahantshetti, N., Garg, B. S., Ravi, M.
10.1101/2022.04.20.22274076 — Posted: 2022-04-26
Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta-plus variants
Moyo-Gwete, T., Madzivhandila, M., Mkhize, N. N., Kgagudi, P., Ayres, F., Lambson, B. E., Manamela, N. P., Richardson, S. I., Makhado, Z., van der Mescht, M., de Beer, Z., de Villiers, T. R., Burgers, W. A., Ntusi, N. A., Rossouw, T., Ueckermann, V., Boswell, M. T., Moore, P. L.
10.1101/2022.04.24.22273395 — Posted: 2022-04-26
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents
Gachoud, D., Pillonel, T., Gerasimos, T., Battola, D., Dumas, D., Opota, O., Fontana, S., Vollenweider, P., Manuel, O., Greub, G., Bertelli, C., Rufer, N.
10.1101/2022.04.24.22274200 — Posted: 2022-04-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).